Drug Target Review

New CRISPR based gene-editing treatment targets root cause of kidney disease

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

Single-dose base editing corrects PKD1 mutation and extends survival in ADPKD preclinical models

Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal dominant polycystic kidney disease (ADPKD), the most common ...
KIMT News 3

Mayo Clinic's gene therapy breakthrough targets most-common kidney disease

The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...

5 Rare Kidney Diseases You May Not Know About

This Rare Disease Day, observed on Feb. 28 worldwide, the American Kidney Fund is committed to improving the understanding of ...
IEEE

Chronic Diseases Prediction Using Machine Learning With Data Preprocessing Handling: A Critical Review

Abstract: According to the World Health Organization (WHO), some chronic diseases such as diabetes mellitus, stroke, cancer, cardiac vascular, kidney failure, and hypertension are essential for early ...

Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome

DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...